3 Neil Woodford High-Income Blue Chips For Your ISA: GlaxoSmithKline plc, SSE PLC And Legal & General Group Plc

Income seekers should take a look at Woodford picks GlaxoSmithKline plc (LON:GSK), SSE PLC (LON:SSE) and Legal & General Group Plc (LON:LGEN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Master equity income investor Neil Woodford knows a thing or two about picking great dividend shares after more than a quarter of a century in the game.

If you’re looking for income ideas for your ISA, GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), SSE (LSE: SSE) and Legal & General (LSE: LGEN) are three Woodford heavyweight high yielders you may want to consider.

GlaxoSmithKline

Big pharma companies have been a feature of Woodford’s funds for most of his career. Despite patent expiries on some blockbuster drugs holding back growth in the industry lately, Woodford reckons the sector “still looks very attractive” for long-term returns for shareholders.

GlaxoSmithKline has been a dividend stalwart over the years. The UK’s top pharma group delivered an 80p a share payout for 2014. At a recent share price of 1,635p, the trailing yield is 4.9% — well above the 3.4% of the FTSE 100 as a whole.

Glaxo has indicated the dividend will be maintained at 80p for 2015. However, the Board also plans to return cash of £4bn (worth another 80p a share or so) to shareholders, following the recent completion of a deal with Swiss group Novartis.

SSE

The UK’s “Big Six” energy companies are currently facing a challenging business environment, an investigation by the Competition and Markets Authority relating to the supply and acquisition of energy, as well as various threats from the Labour Party that could disrupt business and crimp profits.

SSE has said that for its financial year ending 31 March, it intends to raise the dividend in keeping with its policy of increases at least equal to RPI inflation. We could see a payout of 88p, giving a yield of 5.7% at a recent share price of 1,554p.

However, the company expects earnings for the year to come in at about the same level as last year, and says that its ability to increase earnings is “subject to additional risk in 2015/16 and 2016/17”. The dividend may, or may not, come under pressure, but Woodford is sanguine, and has been increasing his holding in SSE in recent months.

Legal & General

There are 15 banks and insurers in the FTSE 100. Woodford is invested in just one: Legal & General. L&G has made a good recovery since the financial crisis, and both earnings and dividends have been rising strongly.

The company hiked the 2014 dividend by 21% to 11.25p, giving a yield of 3.8% at a recent share price of 293p. Now, L&G’s current yield may not be as high as Glaxo’s and SSE’s, but the insurer is set fair for much stronger growth in the next couple of years. Analysts have pencilled in a dividend of 14.5p for 2016, pushing the yield up to close to 5%.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »